Menu ×

HEALTHCARE & PHARMACEUTICAL

Prognostic Biomarkers Market Segmentation by Indication (Oncology, Cardiological Disease, Diabetes, and Others); and by End-User (Hospitals, Diagnosis Centers, Research Institutes, and Others) – Global Demand Analysis & Opportunity Outlook 2030

  • Text Size:

Extensive insights into the Growth of Prognostic Biomarkers Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More

IN THE NEWS

·   February 26, 2019: The Centre for Ocular Research & Education (CORE) and Meso Scale Diagnostics, LLC announced the initiative to use the Meso Scale Discovery platform to identify biomarkers in the tear film.

Global Prognostic Biomarkers Market Highlights over 2020-2030

The global prognostic biomarkers market is estimated to garner a sizeable revenue by growing at a significant CAGR over the forecast period, i.e., 2021–2030. The growth of the market can be attributed to the recurrence of chronic diseases, even after complete treatment. Diseases, such as, cancer, depression, hepatitis B and C, eczema, and autoimmune diseases tend to come back, despite successful treatment, due to genetic structure of patients, or other factors. The recurrence rate of cancer varies from type to type, with breast, bladder, and leukemia cancer having 20-30% chances of recurrence, while ovarian cancer and glioblastoma have 85-90% recurrence rate. Prognostic biomarkers are used to study likely patient health outcome, which is estimated to drive the growth of the market. Moreover, increasing medical research and advancement, along with expanding personal disposable income and health awareness among people is estimated to boost the market growth.  

Prognostic Biomarkers Market

The global prognostic biomarkers market is segmented by indication into oncology, cardiological diseases, diabetes, and others, out of which, the oncology segment is anticipated to hold the largest share in the market during the forecast period on account of high rate of recurrence of cancer, along with increasing prevalence of cancer. According to a report by the World Health Organization (WHO), cancer is the second leading cause of death, causing one out of every six deaths globally. In the year 2020, more than 10 million deaths were caused by cancer. In other report WHO stated that 30% to 50% of the cancer cases can be prevented by avoiding risk factors and early diagnosis.

Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Expenditure

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years. CLICK TO DOWNLOAD SAMPLE REPORT

Global Prognostic Biomarkers Market Regional Synopsis

Regionally, the global prognostic biomarkers market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America region is estimated to garner largest share over the forecast period on the back of increasing health awareness among people, along with high per capita healthcare expenditure by the government. According to other report of the WHO, per capita healthcare expenditure in North America valued around USD 10,050.279 in the year 2018.

The market in the Europe region is estimated to witness highest CAGR over the forecast period owing to the high prevalence of cancer, and other chronic disease, backed by the growing geriatric population and advancing medical facilities.

The market in the Asia Pacific is also projected to record notable growth over the forecast period, owing to the increasing incidences of diseases, such as, diabetes, and hypertension among the exponentially growing population with over 65% of the population in the region suffering from diabetes, backed by the changing lifestyle in the region. Moreover, growing healthcare sector, along with the economic growth in the region, is estimated to boost the market growth.

Prognostic Biomarkers Market

The global prognostic biomarkers market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Market Segmentation

Our in-depth analysis of the global prognostic biomarkers market includes the following segments:

By Indication

  • Oncology
  • Cardiological Disease
  • Diabetes
  • Others

By End-User

  • Hospital
  • Diagnosis Centers
  • Research Institutes
  • Others

Growth Drivers

  • Increasing Cases of Disease Recurrence
  • Growing Health Awareness Among People

Challenges

  • Unavailability of Proper Advanced Technology in Developing Nations
  • High Cost of Prognostics Biomarkers

Top Featured Companies Dominating the Market

  • Meso Scale Diagnostics, LLC
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • PerkinElmer Inc.
  • Myriad Genetics, Inc.
  • Siemens Healthcare GmbH
  • F. Hoffmann-La Roche Ltd
  • Epigenomics AG
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • QIAGEN GmbH
  • Biomarker Technologies, Inc.

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved